PD-L1-negative Non-small-cell Lung Cancer Treated with Nivolumab Plus Ipilimumab During Maintenance Hemodialysis Results in Rapid Initial Progression Followed by a Long-lasting Response-Reference-Cited by-同舟云学术

PD-L1-negative Non-small-cell Lung Cancer Treated with Nivolumab Plus Ipilimumab During Maintenance Hemodialysis Results in Rapid Initial Progression Followed by a Long-lasting Response

Published:2023 Issue: Volume: Page:
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Yano Shohei¹,Uematsu Shinya¹,Kunimune Naohiro¹,Harima Tomoko¹,Yoshida Yuki¹,Takahashi Shota¹,Ito Masahiro¹,Sakamoto Hiroto¹,Nishizaka Yasuo¹

Affiliation:

1. Department of Respiratory Medicine, Osaka Red Cross Hospital, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_2270-23/_pdf

Reference19 articles.

1. 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 394-424, 2018.

2. 2. Voruganti T, Soulos PR, Mamtani R, Presley CJ, Gross CP. Association between age and survival trends in advanced non-small cell lung cancer after adoption of immunotherapy. JAMA Oncol 9: 334-341, 2023.

3. 3. Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 385: 1975-1982, 2015.

4. 4. Janus N, Launay-Vacher V, Thyss A, et al. Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study. Ann Oncol 24: 501-507, 2013.

5. 5. Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 381: 2020-2031, 2019.